Dr. Juergen Mueller joins LGC as Commercial and Strategic Development Director, Oligo-therapeutics
22 Sep 2017
LGC is delighted to announce that Dr Juergen Mueller has joined as Commercial and Strategic Development Director, Oligo-therapeutics.
Juergen brings with him a wealth of knowledge and an extensive global network of contacts in the field of oligo-therapeutics development and manufacture. He has a PhD in synthetic chemistry and maintains links with the University of Basel occasionally teaching chemistry students.
David Griffiths, Managing Director, Pharma & Health Solutons, LGC, said, “I’m delighted to welcome Juergen to our expanding Oligonucleotide team. Juergen will define and deliver growth in our oligo-therapeutic business across the Group. He will develop our existing customer base at Axolabs, Biosearch and our bioanalytical and CMC analytical drug development services (DDS) teams – especially those for whom we are providing discovery and preclinical support as they scale up and progress candidate drugs to the clinic – all of which will help us as we work towards our vision of science for a safer world.”